LEADER 02760nam  2200409z- 450 
001 9910227349803321
005 20210211
035   $a(CKB)4100000000883835
035   $a(oapen)https://directory.doabooks.org/handle/20.500.12854/46251
035   $a(oapen)doab46251
035   $a(EXLCZ)994100000000883835
100   $a20202102d2017      |y         0
101 0 $aeng
135   $aurmn|---annan
181   $ctxt$2rdacontent
182   $cc$2rdamedia
183   $acr$2rdacarrier
200 00$aEmerging Enterobacteriaceae Infections: Antibiotic Resistance and Novel Treatment Options
210   $cFrontiers Media SA$d2017
215   $a1 online resource (115 p.)
225 1 $aFrontiers Research Topics
311 08$a2-88945-189-5 
330   $aEnterobacteriaceae are spread worldwide and the diseases they cause may be fatal especially in immunocompromised patients. Moreover, the high prevalence of ESBL producing Salmonella and Shigella species diseases worldwide suggests major underlying safety issues. According to the World Health Organization (WHO), 2015, approximately 220 million children contract diarrhoeal diseases every year and 96 000 die. As a result, the increase in single or multi drug-resistant foodborne bacterial pathogens is of major public health concern. Moreover, resistance to antimicrobials was found among Salmonella spp and Campylobacter spp from animals and food, and since fluoroquinolones became licensed for use in animal foods, especially for poultry, the rate of fluoroquinolone resistant Salmonella spp and Campylobacter spp in animals and human food, and then in human infections, rapidly increased. To that purpose, the findings of the conducted studies in the book chapters, 1) highlight surveillance studies reporting the occurrence and distribution of resistance to antimicrobial agents, namely, to third generation cephalosporins, carbapenems and fluoroquinolones, 2) describe the mechanisms of transmission of resistance determinants from animals, food products and clinical specimens, that allow implementation of appropriate measures to control their spread and adopt appropriate therapeutic measures, and 3) provide treatment options, useful to medical practice.
517   $aEmerging Enterobacteriaceae Infections
606   $aMicrobiology (non-medical)$2bicssc
610   $acarbapenemases
610   $aEnterobacteriaceae
610   $aESBLs
610   $aResistance
610   $asurveillance
610   $aTreatment
615  7$aMicrobiology (non-medical)
700   $aGhassan M. Matar$4auth$01305975
906   $aBOOK
912   $a9910227349803321
996   $aEmerging Enterobacteriaceae Infections: Antibiotic Resistance and Novel Treatment Options$93028092
997   $aUNINA